Much has been said of this and other companies about the various charts, the number of shorts and days to cover. All interesting, but only to the extent that it offers some speculative perspective.
Having spent my formative years in business with a most notable Fortune 50 firm, the focus was always on revenues and never on the share price. We believed that the share price would reflect the success we had in executing the business. In fact, most good companies focus on executing their model and achieving success; which they would benefit from in an escalating share price through their various stock holding - whether options, or as awards or insider purchases. Having said this, my concern would be if the company was more focused on affecting the share price than on executing its business and, in so doing, using language that would hype their progress or science. That is not happening. What it seems, at least to me, is they have good scientists and good science; they have a leadership team that has improved over the past couple of years; that they have a realistic approach to their future and a clear picture on what needs to be done. It remains that the share price will bob up and down in the absence of real news of progress. However, once given, the movement will be most noticeably and consistently north. For those selling and buying, then rising and repeating, good luck with timing. Even Warren said he has trouble with that…
You lost me in your discourse. This is not US Steel or GE. It's a small speculative biotech and your rules do not apply. There will be no revenues, even when the shares skyrocket to the moon and beyond.
According to their quarterly report, they had revenue.
"For both quarters ended September 30, 2013 and 2012, Dynavax reported total revenues of $2.9 million. Total revenues for the nine months ended September 30, 2013 were $8.4 million compared to $7.9 million for the same period in 2012. "